atezolizumab + abemaciclib + fulvestrant

**atezolizumab + abemaciclib + fulvestrant** is a triple-drug combination that consists of: - **Atezolizumab**, a monoclonal antibody that inhibits PD-L1, acting as an immune checkpoint inhibitor - **Abemaciclib**, a small molecule cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor - **Fulvestrant**, a selective estrogen receptor degrader (SERD) that inhibits and degrades estrogen receptor alpha This combination is investigated as an experimental cancer therapy, particularly for hormone receptor-positive (HR+), HER2-negative breast cancer, aiming to combine immunotherapy, cell cycle inhibition, and hormonal blockade for enhanced antitumor efficacy.